Create Account
Log In
Dark
chart
exchange
Premium
Terminal
Screener
Stocks
Crypto
Forex
Trends
Depth
Close
Check out our API

RLAY
Relay Therapeutics, Inc. Common Stock
stock NASDAQ

At Close
Jul 9, 2026 3:59:58 PM EDT
20.74USD+5.655%(+1.11)4,392,431
17.48Bid   23.33Ask   5.85Spread
Pre-market
Jul 9, 2026 9:19:30 AM EDT
19.59USD-0.199%(-0.04)233
After-hours
Jul 9, 2026 4:00:30 PM EDT
20.75USD+0.048%(+0.01)922,474
OverviewOption ChainMax PainOptionsHistoricalExchange VolumeDark Pool LevelsDark Pool PrintsExchangesShort VolumeShort Interest - DailyShort InterestBorrow Fee (CTB)Failure to Deliver (FTD)ShortsTrendsNewsNews
Jan 4, 2022
07:39AM EST  Relay Therapeutics Doses First Patient In First-in-Human Trial Of RLY-2608 And Begins Expansion Cohorts For RLY-4008   RTTNews
07:33AM EST  Relay Therapeutics Announces Dosing Of First Patient In First-In-Human Trial Of RLY-2608 And Initiation Of Expansion Cohorts For First-In-Human Trial Of RLY-4008   Benzinga
07:30AM EST  Doses first patient in first-in-human trial of RLY-2608, a pan-mutant and isoform-selective PI3K inhibitor   GlobeNewswire Inc
Jan 3, 2022
07:30AM EST  Relay Therapeutics to Present at 40th Annual J.P. Morgan   GlobeNewswire Inc
Dec 10, 2021
07:35AM EST  Relay Therapeutics Reports Preclinical Data Showing Support For Clinical Development Of RLY-2608 As Both Single, In Combo Agent   Benzinga
07:30AM EST  Relay Therapeutics Announces Preclinical Data that Support   GlobeNewswire Inc
Nov 15, 2021
11:21AM EST  Overview Of Value Stocks In The Healthcare Sector   Benzinga
Nov 10, 2021
06:00PM EST  Relay Therapeutics Q3 EPS $(0.66) Misses $(0.64) Estimate   Benzinga
04:09AM EST  Earnings Scheduled For November 10, 2021   Benzinga
Nov 4, 2021
08:14AM EDT  Section 32 Raises $740 Million Venture Fund   PR Newswire
Nov 1, 2021
10:55AM EDT  A Look Into Healthcare Sector Value Stocks   Benzinga
Oct 12, 2021
09:58PM EDT  Relay Therapeutics Announces Pricing of Public Offering of Common   GlobeNewswire Inc
10:58AM EDT  Shares of clinical-stage precision medicine company Relay Therapeutics, Inc. (RLAY) are down 4 percent on Tuesday's trading after the company announced an underwritten public offering of $350 million of shares of its common stock.   RTTNews
08:13AM EDT  The Daily Biotech Pulse: NRx Stitches COVID-19 Drug Partnership, Protara Gets Nod For Starting Bladder Cancer Study, IGM Moves Beyond Oncology   Benzinga
06:08AM EDT  A Peek Into The Markets: US Stock Futures Mostly Flat Ahead Of Earnings   Benzinga
Oct 11, 2021
04:41PM EDT  Relay Therapeutics Reports $350M Common Stock Offering   Benzinga
04:15PM EDT  Relay Therapeutics Announces Proposed Public Offering of Common Stock   GlobeNewswire Inc
Oct 8, 2021
01:33PM EDT  Relay Therapeutics Shares To Resume Trade At 1:50 p.m. EDT   Benzinga
12:24PM EDT  Relay Therapeutics Highlights Interim Data From Bile Duct Cancer Trial   Benzinga
07:18AM EDT  UPDATE: Relay Sees Selecting A Once-Daily Recommended Phase 2 Dose For RLY-4008, Sees Beginning Expansion Cohorts Prior To End Of 2021   Benzinga
07:17AM EDT  UPDATE: Relay Therapeutics Says 'RLY-4008 demonstrated tumor shrinkage in all six pan-FGFR treatment-nave FGFR2 fusion positive cholangiocarcinoma patients with three achieving confirmed partial responses'   Benzinga
06:04AM EDT  Relay Therapeutics Reports Interim Clinical Data Supporting RLY-4008 As Cholangiocarcinoma (FGFR2) Inhibitor   Benzinga
06:00AM EDT  Interim data suggest that RLY-4008 is a highly selective FGFR2 inhibitor that has not shown to be limited by off-target toxicities of hyperphosphatemia (FGFR1) and diarrhea (FGFR4)   GlobeNewswire Inc
Oct 7, 2021
08:51AM EDT  Relay Therapeutics Announces Preclinical Data; Co Says Data Support RLY-2608 As First Known Allosteric Pan-Mutant Selective Inhibitor Of PI3K   Benzinga
08:50AM EDT  RLY-2608 preferentially binds mutant PI3Kat a novel allosteric site discovered by the Dynamo platform   GlobeNewswire Inc
Oct 3, 2021
02:21PM EDT  The Week Ahead In Biotech (Oct. 3-9): ChemoCentryx FDA Decision, Conference Presentations, IPOs and More   Benzinga
Sep 13, 2021
06:00AM EDT  Relay Therapeutics to Present Clinical Data on RLY-4008 and   GlobeNewswire Inc
Aug 30, 2021
10:22AM EDT  5 Value Stocks To Watch In The Healthcare Sector   Benzinga
Aug 23, 2021
10:20AM EDT  5 Value Stocks In The Healthcare Sector   Benzinga
Aug 17, 2021
06:25AM EDT  HC Wainwright & Co. Maintains Buy on Relay Therapeutics, Lowers Price Target to $54   Benzinga
Aug 12, 2021
05:03PM EDT  Relay Therapeutics Q2 EPS $(0.64) Misses $(0.45) Estimate, Sales $844.00K Miss $8.00M Estimate   Benzinga
04:05PM EDT  Company selected RLY-2608 as PI3K mutant inhibitor development candidate and plans to initiate first-in-human study in the first half of 2022   GlobeNewswire Inc
08:09AM EDT  The Daily Biotech Pulse: Xeris Gets OK For Initiating Hyperthyroidism Study, Merck-Eisai Snag FDA Approval For Drug Combo, Decision Day For Jazz Pharma   Benzinga
04:14AM EDT  Earnings Scheduled For August 12, 2021   Benzinga
Aug 9, 2021
11:07AM EDT  The Week Ahead In Biotech (Aug. 8-14): Jazz Pharma FDA Decision, Earnings Deluge and IPOs In The Spotlight   Benzinga
Jul 21, 2021
06:22AM EDT  B of A Securities Initiates Coverage On Relay Therapeutics with Buy Rating, Announces Price Target of $50   Benzinga
Jun 2, 2021
06:00AM EDT  Relay Therapeutics to Participate in Two Upcoming Investor Conferences   GlobeNewswire Inc
May 14, 2021
07:59AM EDT  The Daily Biotech Pulse: CorMedix Slumps On Delay In Resubmission of DefenCath NDA, Apellis Awaits FDA Decision, Vera Therapeutics Debuts   Benzinga
06:00AM EDT  Relay Therapeutics to Participate in Fireside Chat at the Cowen   GlobeNewswire Inc
May 13, 2021
04:29PM EDT  Relay Therapeutics Q1 EPS $(0.47) Up From $(5.99) YoY   Benzinga
04:05PM EDT  Relay Therapeutics, Inc. (Nasdaq: RLAY), a clinical-stage precision medicine company transforming the drug discovery process by combining leading edge computational and experimental technologies, today reported first quarter 2021 financial results.   GlobeNewswire Inc
May 12, 2021
08:57AM EDT  The Daily Biotech Pulse: Minerva, InflaRx Report Positive Data Readouts, Lucira COVID-19 Test Kit Available On Amazon, Decision Day For Heron   Benzinga
May 11, 2021
07:54AM EDT  The Daily Biotech Pulse: FDA Authorizes Pfizer-BioNTech COVID-19 Vaccine For Adolescents, Lilly Strikes R&D Collaboration, Vaccine Stocks Novavax, Inovio Sink On Earnings   Benzinga
May 10, 2021
06:00AM EDT  Relay Therapeutics Strengthens Computational Leadership Team with   GlobeNewswire Inc
May 7, 2021
07:40AM EDT  The Daily Biotech Pulse: Split Verdict For Chemocentryx, NKarta-CRISPR In Cell Therapy Collaboration, Orphazyme's Clinical Trial Setback, 2 IPOs   Benzinga
May 5, 2021
07:43AM EDT  The Daily Biotech Pulse: Athenex, NeoGenomics And Amryt In M&A Mix, European Nod For Roche's Cancer Immunotherapy, Earnings Deluge Continues   Benzinga
06:00AM EDT  Relay Therapeutics to Participate in Fireside Chat at Bank of   GlobeNewswire Inc
May 3, 2021
06:00AM EDT  Relay Therapeutics Expands Clinical Leadership Team with Addition   GlobeNewswire Inc
Apr 16, 2021
06:04AM EDT  Relay Therapeutics Acquires ZebiAI; Relay To Pay $85M Up Front And Up To Additional $85M In Milestones   Benzinga
06:00AM EDT  Relay Therapeutics leadership in this new breed of biotech positions the company asa strategic partner of choice for emerging technologies and founders in these fields   GlobeNewswire Inc
Apr 14, 2021
07:51AM EDT  The Daily Biotech Pulse: Novavax CFO Departs, Zai Lab Inks Cancer Drug Collaboration, FDA Nod For Gilead   Benzinga
Mar 31, 2021
07:41AM EDT  The Daily Biotech Pulse: Pfizer Vaccine 100% Effective In Adolescents, Equillium Readout, Amgen Goes Shopping, Achilles IPO   Benzinga
Mar 30, 2021
08:06AM EDT  The Daily Biotech Pulse: Wave Life Sciences Pulls Plug On 2 Assets, Amarin's Vascepa Snags European Approval, Biocept Jumps On Earnings   Benzinga
Mar 25, 2021
04:10PM EDT  Relay Therapeutics Q4 2020 Net Income $35.3M; Reports FY 2020 Net Loss $52.4M   Benzinga
04:05PM EDT  Advanced two programs, RLY-1971 and RLY-4008, into clinical development, and on track to initiate IND enabling studies with PI3K mutant selective inhibitor in 2021   GlobeNewswire Inc
Mar 10, 2021
04:30PM EST  Relay Therapeutics to Present Preclinical Data on RLY-4008 at AACR   GlobeNewswire Inc
Feb 4, 2021
04:05PM EST  Relay Therapeutics to Participate in Fireside Chat at Guggenheim   GlobeNewswire Inc
Jan 29, 2021
11:45AM EST  JP Morgan Maintains Neutral on Relay Therapeutics, Raises Price Target to $52   Benzinga
Jan 21, 2021
08:05AM EST  The Daily Biotech Pulse: Addex Jumps On Positive Data For Out-Licensed Drug, COVID-19 Vaccine Developer Inovio Announces $150M Follow-On Offering, Boston Scientific Goes Shopping   Benzinga
Jan 12, 2021
02:42AM EST  The lockup period of Relay Therapeutics (RLAY) expires today, i.e., January 12.   RTTNews
Jan 6, 2021
06:00AM EST  Relay Therapeutics to Present at 39th Annual J.P. Morgan   GlobeNewswire Inc
Dec 15, 2020
09:54AM EST  10 Biggest Price Target Changes For Tuesday   Benzinga
06:28AM EST  HC Wainwright & Co. Maintains Buy on Relay Therapeutics, Raises Price Target to $57   Benzinga
Dec 14, 2020
06:25AM EST  Precision medicine company Relay Therapeutics, Inc. (RLAY) announced Monday that it has entered into a worldwide license and collaboration agreement with Roche Group subsidiary Genentech Inc. for the development and commercialization of RLY-1971, a potent inhibitor of SHP2.   RTTNews
06:10AM EST  Relay Therapeutics Announces Worldwide License And Collaboration Deal With Genentech For RLY-1971   RTTNews
06:01AM EST  Relay Therapeutics Announces a Worldwide License and Collaboration Agreement with Genentech for RLY-1971; Relay To Receive $75M Upfront And Is Eligible For $25M In Near-term Payments And $695M In Additional Potential Milestones   Benzinga
06:00AM EST  Collaboration brings together clinical stage SHP2 and KRAS G12C inhibitors   GlobeNewswire Inc
Dec 8, 2020
09:36AM EST  Benzinga's Top Upgrades, Downgrades For December 8, 2020   Benzinga
07:26AM EST  JMP Securities Initiates Coverage On Relay Therapeutics with Market Outperform Rating, Announces Price Target of $66   Benzinga
Nov 25, 2020
07:35AM EST  The Daily Biotech Pulse: Revance's DAXI Regulatory Decision, Reata Slips On FDA Feedback, Liquidia Setback   Benzinga
Nov 18, 2020
07:30AM EST  The Daily Biotech Pulse: Kazia Jumps On Data Readout, Clinical Hold On Cellectis' Blood Cancer Study Lifted   Benzinga
Nov 12, 2020
04:21PM EST  Relay Therapeutics Q3 EPS $(3.00) Up From $(5.53) YoY   Benzinga
Nov 5, 2020
10:28AM EST  Benzinga's Top Upgrades, Downgrades For November 5, 2020   Benzinga
06:11AM EST  HC Wainwright & Co. Initiates Coverage On Relay Therapeutics with Buy Rating, Announces Price Target of $54   Benzinga
Sep 3, 2020
04:12PM EDT  Relay Therapeutics Announces Dosing of First Patient in First-in-Human Clinical Trial of RLY-4008, a Highly Selective FGFR2 Inhibitor   Benzinga
04:05PM EDT  Relay Therapeutics Announces Dosing of First Patient in   GlobeNewswire Inc
Aug 27, 2020
06:54AM EDT  Relay Therapeutics Q2 EPS $(6.06)   Benzinga
06:50AM EDT  Relay Therapeutics, Inc. (Nasdaq: RLAY), a clinical-stage precision medicine company transforming the drug discovery process by leveraging unparalleled insights into protein motion, today reported second quarter 2020 financial results.   GlobeNewswire Inc
Jul 20, 2020
04:05PM EDT  Relay Therapeutics Announces Closing of Initial Public Offering   GlobeNewswire Inc
05:11AM EDT  80 Biggest Movers From Friday   Benzinga
Jul 17, 2020
05:08AM EDT  64 Biggest Movers From Yesterday   Benzinga
Jul 16, 2020
12:01PM EDT  Relay Therapeutics Opens For Share At $35; IPO Priced At $20/Share   Benzinga
06:19AM EDT  Relay Therapeutics Prices 20M Share IPO @$20/Share   Benzinga
Jul 15, 2020
08:51PM EDT  Relay Therapeutics Announces Pricing of Initial Public Offering   GlobeNewswire Inc


Share
About
Pricing
Policies
Markets
API
Info
tz UTC-4
Connect with us
ChartExchange Email
ChartExchange on Discord
ChartExchange on X
ChartExchange on Reddit
ChartExchange on GitHub
ChartExchange on YouTube
© 2020 - 2026 ChartExchange LLC